These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 10772372)

  • 1. Impact of pharmacy counseling on compliance and effectiveness of combination lipid-lowering therapy in patients undergoing coronary artery revascularization: a randomized, controlled trial.
    Faulkner MA; Wadibia EC; Lucas BD; Hilleman DE
    Pharmacotherapy; 2000 Apr; 20(4):410-6. PubMed ID: 10772372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intensive combination drug therapy of familial hypercholesterolemia with lovastatin, probucol, and colestipol hydrochloride.
    Witztum JL; Simmons D; Steinberg D; Beltz WF; Weinreb R; Young SG; Lester P; Kelly N; Juliano J
    Circulation; 1989 Jan; 79(1):16-28. PubMed ID: 2642754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B.
    Brown G; Albers JJ; Fisher LD; Schaefer SM; Lin JT; Kaplan C; Zhao XQ; Bisson BD; Fitzpatrick VF; Dodge HT
    N Engl J Med; 1990 Nov; 323(19):1289-98. PubMed ID: 2215615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid-lowering therapy after coronary artery bypass grafting: time for more aggressive intervention.
    Lucas BD
    Am J Health Syst Pharm; 2002 Nov; 59(21):2101-3. PubMed ID: 12434726
    [No Abstract]   [Full Text] [Related]  

  • 5. Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density.
    Zambon A; Hokanson JE; Brown BG; Brunzell JD
    Circulation; 1999 Apr; 99(15):1959-64. PubMed ID: 10208998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination drug therapy for familial combined hyperlipidemia.
    East C; Bilheimer DW; Grundy SM
    Ann Intern Med; 1988 Jul; 109(1):25-32. PubMed ID: 3288029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol <100 mg/dl in patients with hyperlipidemia and coronary artery disease.
    Brown BG; Bardsley J; Poulin D; Hillger LA; Dowdy A; Maher VM; Zhao XQ; Albers JJ; Knopp RH
    Am J Cardiol; 1997 Jul; 80(2):111-5. PubMed ID: 9230143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group.
    Pasternak RC; Brown LE; Stone PH; Silverman DI; Gibson CM; Sacks FM
    Ann Intern Med; 1996 Oct; 125(7):529-40. PubMed ID: 8815751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of the apolipoprotein E phenotype on cholesteryl ester transfer protein activity, plasma lipids and apolipoprotein A I levels in hypercholesterolaemic patients on colestipol and lovastatin treatment.
    Korhonen T; Hannuksela ML; Seppänen S; Kervinen K; Kesäniemi YA; Savolainen MJ
    Eur J Clin Pharmacol; 1999 Feb; 54(12):903-10. PubMed ID: 10192749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of combined diet and colestipol in long-term (7--7 1/2 years) treatment of patients with type II hyperlipoproteinemia.
    Kuo PT; Hayase K; Kostis JB; Moreyra AE
    Circulation; 1979 Feb; 59(2):199-211. PubMed ID: 215338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of colestipol and clofibrate, singly and in combination, on plasma lipid and lipoproteins in type IIb hyperlipoproteinemia.
    Hunninghake DB; Bell C; Olson L
    Metabolism; 1981 Jun; 30(6):610-5. PubMed ID: 7231198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Common hepatic lipase gene promoter variant determines clinical response to intensive lipid-lowering treatment.
    Zambon A; Deeb SS; Brown BG; Hokanson JE; Brunzell JD
    Circulation; 2001 Feb; 103(6):792-8. PubMed ID: 11171785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized pilot trial of low-dose combination lipid-lowering therapy following coronary artery bypass grafting.
    Barbir M; Hunt BJ; Galloway D; Taylor A; Ilsley C; Mitchell A; Yacoub M
    Clin Cardiol; 1994 Feb; 17(2):59-64. PubMed ID: 8162627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Familial Hypercholesterolaemia Regression Study: a randomised trial of low-density-lipoprotein apheresis.
    Thompson GR; Maher VM; Matthews S; Kitano Y; Neuwirth C; Shortt MB; Davies G; Rees A; Mir A; Prescott RJ
    Lancet; 1995 Apr; 345(8953):811-6. PubMed ID: 7898227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetically determined apo B levels and peak LDL density predict angiographic response to intensive lipid-lowering therapy.
    Zambon A; Brown BG; Hokanson JE; Motulsky AG; Brunzell JD
    J Intern Med; 2006 Apr; 259(4):401-9. PubMed ID: 16594908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin.
    Hodis HN; Mack WJ; Azen SP; Alaupovic P; Pogoda JM; LaBree L; Hemphill LC; Kramsch DM; Blankenhorn DH
    Circulation; 1994 Jul; 90(1):42-9. PubMed ID: 8026027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.
    Downs JR; Clearfield M; Weis S; Whitney E; Shapiro DR; Beere PA; Langendorfer A; Stein EA; Kruyer W; Gotto AM
    JAMA; 1998 May; 279(20):1615-22. PubMed ID: 9613910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are high density lipoprotein (HDL) and triglyceride levels relevant in stroke prevention?
    Rizos E; Mikhailidis DP
    Cardiovasc Res; 2001 Nov; 52(2):199-207. PubMed ID: 11684067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug therapy for hypercholesterolemia in patients with cardiovascular disease: factors limiting achievement of lipid goals.
    Schectman G; Hiatt J
    Am J Med; 1996 Feb; 100(2):197-204. PubMed ID: 8629655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized crossover study of gemfibrozil versus lovastatin in familial combined hyperlipidemia: additive effects of combination treatment on lipid regulation.
    Zambón D; Ros E; Rodriguez-Villar C; Laguna JC; Vázquez M; Sanllehy C; Casals E; Sol JM; Hernández G
    Metabolism; 1999 Jan; 48(1):47-54. PubMed ID: 9920144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.